Form4insider filings, from the source

SEC Form 4 · accession 0001140361-18-019768

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Apr 24, 2018
Accepted (ET)
Apr 26, 2018 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockApr 24, 2018M7,500$1.184A190,207D
Common StockF2,F3Apr 24, 2018S1,717$129.3516D188,490D
Common StockF2,F4Apr 24, 2018S1,283$130.6232D187,207D
Common StockF2,F5Apr 24, 2018S1,500$131.7567D185,707D
Common StockF2,F6Apr 24, 2018S2,490$132.5426D183,217D
Common StockF2,F7Apr 24, 2018S510$133.4851D182,707D
Common StockApr 25, 2018M7,500$1.184A190,207D
Common StockF2,F8Apr 25, 2018S800$128.3045D189,407D
Common StockF2,F9Apr 25, 2018S800$129.4438D188,607D
Common StockF2,F10Apr 25, 2018S2,400$130.7121D186,207D
Common StockF2,F11Apr 25, 2018S3,400$131.8418D182,807D
Common StockApr 25, 2018S100$132.53D182,707D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F12$1.184Apr 24, 2018M7,500D—Nov 14, 2023Common Stock7,50037,190D
Employee Stock Option (right to buy)F12$1.184Apr 25, 2018M7,500D—Nov 14, 2023Common Stock7,50029,690D

Explanation of responses